Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 1,738 trials

Advanced Solid Tumors: XON7 Antibody Study

We are investigating a new antibody treatment for patients with advanced or metastatic solid tumors. This study aims to evaluate its safety and how well it works in treating these cancers.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: STAR0602 Treatment

We are testing a new drug, STAR0602, to see if it can help stimulate the immune system in patients with advanced solid tumors that cannot be surgically removed. This study aims to explore its effects on tumors that have spread locally or to other parts of the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

TOS-358 for Adults with Solid Tumors

We are testing a new treatment called TOS-358 in adults with solid tumors. This study aims to understand how safe it is and how well it works.

Malignant Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are analyzing how well sacituzumab govitecan works for patients with advanced breast cancer. The study will also assess safety and explore biomarkers that may predict treatment response.

Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Chronic Lymphocytic Leukemia: Venetoclax and Acalabrutinib Treatment

We are studying a combination of venetoclax and acalabrutinib for patients with CLL who have relapsed after previous treatment. The goal is to see if this combination can help achieve better disease control and improve quality of life.

Chronic Lymphocytic LeukemiaPatients with Relapsed CLL>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Small Bowel Adenocarcinoma: FOLFIRINOX vs. FOLFOX

We are studying two chemotherapy treatments for patients with locally advanced or metastatic small bowel adenocarcinoma. The goal is to find out which treatment helps patients live longer without their cancer worsening.

Small Bowel Adenocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

B-cell Non-Hodgkin Lymphoma: CARCIK-CD19 Cell Therapy

We are studying a new cell therapy for adults and children with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The trial aims to evaluate the safety and effectiveness of this treatment.

B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Psilocybin for Cancer-Related Depression

We are studying whether a single dose of psilocybin can help improve mood in adults aged 20-80 with major depression after a cancer diagnosis. Participants will compare its effects to a lower dose to assess changes in depressive symptoms.

Malignant TumorsMajor Depressive Disorder6-12 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteOncologyPsychiatry

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Hereditary Ichthyosis: Injectable Gentamicin Study

We are studying whether injectable gentamicin can improve skin scaling and redness in people with hereditary ichthyosis. This trial aims to assess its effects on skin condition and overall quality of life.

Congenital Ichthyosis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatology